FLT3 inhibitors in acute myeloid leukemia

FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclini...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Mei, Li, Chuntuan, Zhu, Xiongpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280371/
https://www.ncbi.nlm.nih.gov/pubmed/30514344
http://dx.doi.org/10.1186/s13045-018-0675-4
_version_ 1783378655202770944
author Wu, Mei
Li, Chuntuan
Zhu, Xiongpeng
author_facet Wu, Mei
Li, Chuntuan
Zhu, Xiongpeng
author_sort Wu, Mei
collection PubMed
description FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents.
format Online
Article
Text
id pubmed-6280371
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62803712018-12-10 FLT3 inhibitors in acute myeloid leukemia Wu, Mei Li, Chuntuan Zhu, Xiongpeng J Hematol Oncol Review FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents. BioMed Central 2018-12-04 /pmc/articles/PMC6280371/ /pubmed/30514344 http://dx.doi.org/10.1186/s13045-018-0675-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wu, Mei
Li, Chuntuan
Zhu, Xiongpeng
FLT3 inhibitors in acute myeloid leukemia
title FLT3 inhibitors in acute myeloid leukemia
title_full FLT3 inhibitors in acute myeloid leukemia
title_fullStr FLT3 inhibitors in acute myeloid leukemia
title_full_unstemmed FLT3 inhibitors in acute myeloid leukemia
title_short FLT3 inhibitors in acute myeloid leukemia
title_sort flt3 inhibitors in acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280371/
https://www.ncbi.nlm.nih.gov/pubmed/30514344
http://dx.doi.org/10.1186/s13045-018-0675-4
work_keys_str_mv AT wumei flt3inhibitorsinacutemyeloidleukemia
AT lichuntuan flt3inhibitorsinacutemyeloidleukemia
AT zhuxiongpeng flt3inhibitorsinacutemyeloidleukemia

Ejemplares similares